This provider's $887.6M in total Medicare payments ranks in the 99th percentile of Clinical Laboratory providers nationally.
Medicare payments to this provider grew 74% from 2014 to 2023.
78% of their billing comes from a single procedure code (81519 — Test for detecting genes associated with breast cancer).
AI-generated analysis based on Medicare payment data.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2014 | $4.2K | $3.1K | 1.34x | $1.0K | $55.7M | 17.8K | 3 |
| 2015 | $4.3K | $3.2K | 1.37x | $1.2K | $59.7M | 18.9K | 3 |
| 2016 | $4.4K | $3.2K | 1.40x | $1.3K | $69.1M | 21.8K | 4 |
| 2017 | $4.5K | $3.2K | 1.40x | $1.3K | $75.5M | 23.7K | 4 |
| 2018 | $4.5K | $3.5K | 1.28x | $975.44 | $98.3M | 27.9K | 6 |
| 2019 | $4.6K | $3.7K | 1.22x | $828.20 | $111.1M | 29.6K | 5 |
| 2020 | $4.5K | $3.7K | 1.21x | $778.65 | $96.5M | 26.2K | 6 |
| 2021 | $4.6K | $3.8K | 1.22x | $839.32 | $116.3M | 30.8K | 7 |
| 2022 | $4.6K | $3.8K | 1.23x | $850.93 | $108.5M | 28.8K | 8 |
| 2023 | $4.5K | $3.6K | 1.24x | $851.51 | $96.8M | 26.7K | 5 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| 81519 | Test for detecting genes associated with breast cancer | 188.0K | $691.1M | $3.7K | 1.25x |
| 81479 | Molecular pathology procedure | 21.6K | $67.3M | $3.1K | 1.44x |
| 0047U | Mrna gene analysis of 17 genes in prostate tumor tissue | 16.9K | $63.7M | $3.8K | 1.20x |
| 84999 | Chemistry procedures | 12.0K | $40.0M | $3.3K | 1.33x |
| 81525 | Gene analysis (colon related cancer) | 3.2K | $9.7M | $3.1K | 1.45x |
| 0244U | Gene analysis of 257 genes associated with solid organ cancer in tumor tissue sample, comprehensive genomic profiling | 2.4K | $7.6M | $3.2K | 1.65x |
| 0045U | Mrna gene analysis of 12 genes in breast ductal carcinoma in situ tumor tissue | 1.8K | $6.7M | $3.7K | 1.25x |
| 0329U | Exome and transcriptome sequence analysis of dna and rna from tumor with dna from normal blood or saliva for subtraction, report of clinically significant mutations with therapy associations | 334 | $953.4K | $2.9K | 2.52x |
| 88342 | Tissue or cell analysis by immunologic technique | 2.9K | $290.4K | $100.69 | 1.52x |
| 88360 | Microscopic genetic analysis of tumor, manual | 2.0K | $117.3K | $59.78 | 1.49x |
| G0461 | Immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain | 544 | $47.5K | $87.30 | 1.74x |
| G0462 | Immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure) | 544 | $37.6K | $69.20 | 2.20x |
This provider submits charges 1.28 times higher than what Medicare actually pays.
A markup ratio of 1.28x means for every $100 Medicare pays, this provider initially charges $128. This is lower than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Clinical Laboratory providers in CA for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Unilab Corporation | West Hills, CA | $868.8M | ⚠️ Flagged |
| Caredx Inc. | Brisbane, CA | $751.0M | ✓ Clear |
| Laboratory Corporation Of America | San Diego, CA | $592.4M | ⚠️ Flagged |
| Millennium Health, Llc | San Diego, CA | $587.9M | ✓ Clear |
| Guardant Health, Inc. | Redwood City, CA | $498.0M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data